The Medicines and Healthcare products Regulatory Agency approved vimseltinib, marketed as Romvimza, on 14 August 2026 for use in adults with tenosynovial giant cell tumour. The marketing authorisation covers patients whose condition affects movement or for whom surgery is not an appropriate option, giving the UK a licensed treatment route for a rare but potentially disabling joint disease. In the MHRA announcement, Julian Beach, the agency's Executive Director of Healthcare Quality and Access, said the decision reflects the regulator's dual task of supporting access to effective medicines while continuing to review safety after approval. The authorisation was granted to Deciphera Pharmaceuticals.
TGCT is not a cancer, but the condition can still carry a substantial burden on day-to-day function. According to the MHRA, it usually develops around a single joint and its surrounding tendons, most often in the knee or ankle, and is seen mainly in young and middle-aged adults. That clinical profile matters for policy and service planning because the treatment issue is often about preserving movement rather than responding to malignancy. Pain, swelling, stiffness and restricted mobility can lead to repeated specialist review, imaging, surgery discussions and longer-term effects on work and independence.
The MHRA said the active substance, vimseltinib, works by blocking proteins involved in the growth of TGCT, helping to slow tumour development. The medicine is supplied as a capsule and should be swallowed whole with water, with or without food, twice a week. In practice, that creates a non-operative option within the terms of the licence for adults whose symptoms are affecting movement and whose surgical options are limited. It does not remove the need for specialist assessment, but it may change how clinicians sequence treatment where repeated or complex surgery is not suitable.
The approval is also notable for the regulatory route used. The MHRA said the application was submitted and approved through the International Recognition Procedure, Route B. For policy readers, the significance is straightforward. The International Recognition Procedure allows the MHRA to use assessments from recognised international regulators as part of its review while still issuing its own UK decision on quality, safety and efficacy. That route is designed to support timely access to suitable medicines without removing domestic regulatory oversight.
Safety controls remain a prominent part of the decision. The MHRA has placed vimseltinib under additional monitoring and has stated that the medicine must not be used in pregnancy. The side-effect profile set out by the regulator is material for prescribers and patients alike. The most common adverse reactions, affecting more than one in five people, include tiredness, swelling around the eyes, ankles and feet, itching, rash, high blood pressure, raised liver enzymes, higher cholesterol, raised creatinine and reduced neutrophil counts.
This means the authorisation is not simply an access announcement. In routine use, the medicine is likely to require structured follow-up covering symptoms, blood pressure and laboratory markers, with clear advice for patients on when to contact their clinical team. The MHRA has advised patients to take vimseltinib exactly as prescribed and to discuss any side effects with a doctor or pharmacist. Suspected adverse reactions can also be reported through the Yellow Card scheme, which remains a key part of UK medicines surveillance once a product is in clinical use.
Further technical detail is due shortly. The MHRA said the Summary of Product Characteristics and the Patient Information Leaflet will be published on the MHRA Products website within seven days of approval, providing the formal reference documents for prescribing, contraindications and monitoring. The wider meaning of the decision is that the UK now has a licensed vimseltinib option for adults with TGCT when surgery is not suitable or movement is materially affected. The next step is implementation through specialist pathways, with providers needing to determine where the medicine fits in care models while maintaining close pharmacovigilance.